Professor Tom MacDonald

Professor Tom MacDonald is a Professor of Clinical Pharmacology & Pharmacoepidemiology at the University of Dundee and Honorary Consultant Physician at Ninewells Hospital & Medical School, Dundee, Scotland, UK.  He is also the Director of MEMO Research and the Hypertension Research Centre (HRC) within the Medical School at the University.  He is the Co-Chair of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).  Currently, he is the principal investigator of a large, multi- national, multi-centre streamlined safety study, Febuxostat versus Allopurinol Safety Trial (FAST).    He is also the PI for the Treatment In the Morning versus Evening (TIME) study which has randomised >21,000 patients.  He is active in a number of learned societies and is a past president of both the International Society of Pharmacoepidemiology (ISPE) and the British & Irish Hypertension Society (BIHS).  He has published extensively on hypertension, cardiovascular disorders and safety of medicines, especially the safety of non-steroidal anti- inflammatory drugs (NSAIDs).

A few of Professor Tom MacDonad’s Publications:

1. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
   Lancet. 2015;387:1373-4.
2. Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society’s Prevention; Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
   Lancet Diabetes Endocrinol. 2016;4:136-47.
3. MacDonald TM, Hawkey CJ,  Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS. Randomised trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: The Standard care versus Celecoxib Outcome Trial (SCOT).
   European Heart Journal 2017;38:1843-1850
4. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ. Combination Therapy is superior to Sequential Monotherapy for the Initial Treatment of Hypertension: a double-blind randomised controlled trial. Journal of the American Heart Association 2017 Nov 18;6(11). pii: e006986.
5. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018 Apr 11. pii: S2213-8587(18)30071-8